

Environmental Health Risk Management Plan (EHRMP)

Intas Pharmaceutical Limited

Proposal entitled Development of a DNA Electroporation device to facilitate development of DNA -based COVID-19 vaccine candidates

(i) Brief description of the proposed activity

Plasmid DNA have been established for its safety in human subjects and therefore, current project aims to develop plasmid DNA based COVID-19 vaccine and evaluating their in vivo immunogenicity post administration via electroporation.

Plasmid production

The competent *E. coli* cells are transformed with individual plasmid encoding antigenic variants of spike protein of SARS-CoV-2 vectors. The research microbial cell banks are prepared and characterized. The characterized microbial banks are used for large scale endotoxin-free plasmid preparation. QC for identity, purity and sterility will be done and the produced plasmids will be used for vaccination using electroporation approach.

(ii) List of environment related regulatory clearances required for the activity.

1. Review Committee on Genetic Manipulation (RCGM)
2. Institutional Biosafety Committee (IBSC)
3. Consent/ authorization from respective PCB for following:
 - Water (Prevention & Control of Pollution) Act, 1974 and Water (Prevention & Control of Pollution) Rules, 1975.
 - Air (Prevention & Control of Pollution) Act, 1981.
 - The Environment Protection Act, 1986 and The Environment Protection Rules, 1986.
 - Municipal Solid Waste (Management and Handling) Rules, 2016.
 - The Noise Pollution (Regulation and Control) Rules, 2000.
 - E-Waste Management and Handling Rules, 2016.
 - Bio-medical Waste Management and Handling Rules, 2016.

Institutional Arrangement

Area of Risk		Yes	No	Details	Proposed Plan
1.	Is there a designated full-time staff for Environment Health and Safety (EHS) issues?	X		EHS Org Chart in place	The concerned staff will be trained on the Environment Health and Safety (EHS) and will comply with the norms and requirements of the Pollution Control Committee.

Environmental Health Risk Management Plan (EHRMP)

Intas Pharmaceutical Limited

2.	Does the EHS staff handle the following?			Currently Intas Biopharma handles the following. EOHS, Waste management, Consents and regulatory clearances, record keeping of accidents and procedures and EHS training. We will comply to Environment Management Framework compliance for Innovate in India Project.
	Occupational Health and Safety	X		
	Waste Management	X		
	List of consents and regulatory clearances	X		
	Record keeping of accidents and procedures	X		
	EHS trainings for staff	X		
	Environment Management Framework compliance for Innovate in India Project	X		
3.	Is there a reporting structure in place regarding EHS issues?	X		Describe: As per EOHS Policy EHS/PY/002-02. The reporting structures is in place and shall be updated and maintained.
4.	Are regular EHS trainings provided to staff?	X		Frequency: Fire Drill: Every two months EHS awareness training to staff: Annual. Other Safety Trainings: As per training matrix Training records will be provided upon request and further training will be conducted as per the schedule.
5.	Institutional Bio-Safety Committee (IBSC)	X		IBSC is already in place for site. Periodic review meetings will be scheduled and proper approvals will be taken from the IBSC Committee.
6.	Ethics Committee (EC)		X	Not available at Intas The CRO that will

Environmental Health Risk Management Plan (EHRMP)

Intas Pharmaceutical Limited

				premises.	be involved in animal studies, would have Institutional Ethics Committee to conduct the study.
General Occupational Health and Safety					
	Area of Risk	Yes	No	Details	Proposed Plan
7.	Are there Standard Operating Procedures for accidents, hazards, and other emergencies (chemical spills, heat hazards, fire hazards, radioactive hazards etc.)?	X		EHS policy (EHS/PY/002-02) available	Already in place and will follow SOP's.
8.	Are the following in place?			Chemical spill kits	Already in place and this safety measure will be maintained in working condition.
	Chemical spill kits	X		Eye wash	
	Eye wash	X		Shower stations	
	Shower stations	X		First Aid Kit	
	First Aid Kit	X		Fire Extinguishers	
	Fire Extinguishers	X		Register of accidents and injuries are available at the premises.	
9.	Are proper signage and storage system in place?	X		Bio-safety manual	These would be regularly updated/replaced.
	Display of Material Safety Data Sheet (MSDS) where relevant	X		Proper signage and storage system are available at Intas Biopharma premises.	
	Display of emergency numbers and procedures (Person to Contact, Doctor, Ambulance, Fire Emergency, Police) displayed in all critical Places	X		Display of Material Safety Data Sheet (MSDS) where relevant is available.	
	Signage across the facility (labs, storage, hazardous areas, etc.)	X		Display of emergency numbers and procedures are displayed at all critical places.	
	Are flammable materials appropriately stored to prevent fire hazards?	X		Signage across the facility (labs, storage, hazardous areas, etc.) are displayed. Flammable materials are appropriately stored to prevent fire hazards	

Environmental Health Risk Management Plan (EHRMP)

Intas Pharmaceutical Limited

10.	Are smoke detectors, fire alarms, automatic safety/shut off systems, overflow preventors, etc. in place and regularly maintained?	X		Smoke detectors, fire alarms, automatic safety/shutoff systems, overflow preventers are available at Intas Biopharma premises.	Already in place and will ensure that they are properly maintained and in working condition.
11.	Are there control measures for VOC, air emissions, high operating temperatures, pathogens/vectors etc. in place?	X		Control measures for VOC, air emissions and high operating temperatures, pathogens/vectors are available at Intas manufacturing sites.	Already in place will be ensured throughout the Project.
12.	Are regular mock drills conducted for emergency preparedness and safety?	X		Frequency (type wise): Fire Drills every six months	Records of mock drills available and the mock drills are being conducted regularly.
13.	Are staff provided with OHS training?	X		Describe: Annual OHS Training program is conducted for all the staff.	Records for training are available and will be produced upon request by any authority. Trainings will be continued.

Biomedical Waste (BMW)

	Area of Risk	Yes	No	Details	Proposed Plan
14.	Is there generation of biomedical waste (as described in Bio-Medical Waste Management Rules, 2016) in the grantee?	X		As per BMW authorization form – III (Rule 10, 2016 under the EPCACT'86) GPCB has permitted Intas for handling BMW for the following (KG/Month) BMW Auth No. 349187, valid upto 31/12/2075 Yellow waste-480 Kg White waste (translucent) – 150 Kg Red waste – 10 Kg Blue waste – 120 Kg	We will revise our SOP - SOP_GT_014_00 Disposal of waste as per BMW rule 2016 and implement procedure accordingly.

Environmental Health Risk Management Plan (EHRMP)

Intas Pharmaceutical Limited

15.	Is there trained staff to handle biomedical waste in the grantee?	X		EHS team train staff annually as per training matrix	The trainings will be continued.	
16.	Has the grantee obtained authorization from State Pollution Control Board /Pollution Control Committee?	X		Gujarat pollution control board consent number AWH-103574 date of issue -19 Aug 2019 and valid till 26 Aug 2024.	The provisions in the authorization will be adhered.	
17.	Is the biomedical waste segregated at point of generation in the facility and stored in suitable containers?	X		Yellow	Yes	We will revise our SOP - SOP_GT_014_00 Disposal of waste as per BMW rule 2016 and implement procedure accordingly.
				Red	Yes	
				White	No	
				Blue	No	
18.	Is the bar code system for the segregated waste in place?		X	The bar code system is not applicable Intas Biopharma site.	we will initiate procedure to manage biomedical waste via barcode system on or before 1 st Feb 2021.	
19.	Is the biomedical waste being sent to an authorized common BMW facility?	X		Name and address of CBMWF: Ecoli waste management PVT Ltd. Plot No. 14/1, Saket Industrial estate, Village Moraiya, Tal Sanand, Ahmedabad 382210 Distance from facility: 3 KM	As per Suggestion, we will revise our SOP - SOP_GT_014_00 Disposal of waste as per BMW rule 2016 and implement procedure accordingly.	

Environmental Health Risk Management Plan (EHRMP)

Intas Pharmaceutical Limited

				<p>Frequency and Mode of transport: Daily, Ecoli waste management PVT Ltd. authorized vehicle</p> <p>Who transports? Ecoli waste management PVT Ltd.</p>	
20.	Does the grantee have an in-house BMW treatment facility?		X	Reason: Biological liquid waste treated at in-house water treatment facility.	As per Suggestion, we will revise our SOP - SOP_GT_014_00 Disposal of waste as per BMW rule 2016 and implement procedure accordingly.
	Is the treatment facility own (individual)?	X		Authorization: GPCB	
	Is the treatment facility a shared facility in an industrial park?	X		<p>Distance of nearest CBWM from facility: 10 Km</p> <p>Types of treatment: autoclave, incinerator, scrubber, microwave</p>	
21.	Are lab waste, microbiological waste and chemical liquid waste pre-treated before storing and sending to treatment facilities according to guidelines prescribed in BWM, 2016 regulations?	X		<p>Types of treatment: SP-PR-044- Handling of Biomedical Waste Materials. IBPL-M-QA-001 Biosafety module</p>	The waste treatment as per guidelines prescribed in BWM, 2016 regulations and the Biosafety manual are followed at the current facility. Compliance calendar shall be maintained.
22.	Is the liquid waste checked for active cells before sending to treatment plant?	X		SOP: SOP/GT/014 – Disposal of waste (Intas Gene therapy R&D lab)	As per suggestion, we will perform test to check active cells in liquid waste by every 3 month and revise our SOP accordingly (SOP/GT/014)
23.	Are necessary waste pre-treatment equipment in place?	X		List of equipment: autoclaves, serological	Standard equipment already in place and

Environmental Health Risk Management Plan (EHRMP)

Intas Pharmaceutical Limited

	Do the equipment adhere to prescribed norms by State Pollution Control Board (SPCB)?	X		<p>pipette holders with hypochlorite solution and essential equipment for ETP.</p> <p>Details of waste pre-treatment: chemical inactivation or steam sterilization, pH adjustment and finally ETP.</p>	will be utilized effectively.
24.	Are chlorinated plastic gloves and bags phased out in the grantee?	X		Not under use	Usage of latex and nitrile gloves are the only practice followed at Intas Biopharma
25.	Are grantee's personnel involved in handling BMW provided with regular training?	X		<p>Frequency: Once a Year</p> <p>Trainer: EHS Personnel</p>	Training is being provided and will be provided regularly.
26.	Are medical examination provided to personnel involved in BMW waste handling and are they provided with relevant immunization like Hepatitis B and Tetanus?	X		<p>Frequency of medical examination: Once a Year</p> <p>SP-EH-001: Routine (Post Employment) Medical Examination, Intas Biopharma.</p> <p>Practice in place to immunize all the personnel involved in the BMW.</p>	Reports will be maintained.
27.	Is a daily register for biomedical waste maintained including accident reporting record?	X		<p>Currently there is a register for biological waste maintained. Accident reporting is governed by EHS/PY/002-02 : Policy on Accident / Incident Management</p>	Already in place and the register for biological waste shall be maintained.
28.	Are annual reports on BWM submitted to SPCB as per required form (see Bio-	X		Form 04 (form for filling annual returns by	The annual submission will be

Environmental Health Risk Management Plan (EHRMP)

Intas Pharmaceutical Limited

	Medical Waste Rules 2016)?			occupier or operator of facility) submitted annually	continued.
Hazardous Waste (HW)					
	Area of Risk	Yes	No	Details	Proposed Plan
29.	Is there generation of hazardous waste (as per Hazardous Waste Rules, 2016) in the grantee?	X		<p>If Yes, provide a list of hazardous waste produced in the facility</p> <p>used oils from DG set with our registered partner shana oil process</p> <p>Shana Oil process, near good luck market, chandola lake, Ahmedabad 380023.</p> <p>Valid consent available at site for water, air, hazardous waste from GPCB</p>	<p>The hazardous waste generated is handed over to authorized hazardous waste recycler and hence there is no harm to environment and health. This process will be continued throughout the project.</p> <p>Used oils from DG set with our registered partner shana oil process and they are approved recycler by SPCB</p>
30.	Is there trained staff in the facility to identify and handle hazardous waste?	X		There are trained EHS personnel who would identify and handle hazardous waste	Our EHS team are trained to handle hazardous waste.
31.	Does the grantee have authorization from SPCB for hazardous waste?	X		Valid consent available	Valid consent shall be made available upon request. Timely renewals will be made with proper approvals as and when required.
32.	Is there a secure location for storage of HW with proper signage?	X		Secure location is available for storage of HW.	At out location we are not processing used oil in ETP. Location: We have specific location for intermediate storage for hazardous waste
	Are hazardous waste stored for more than 90 days in the grantee's premises?		X		

Environmental Health Risk Management Plan (EHRMP)

Intas Pharmaceutical Limited

					and we follow GPCB consent guideline with manifest.
33.	Is the hazardous being send to an authorized disposal facility or user?	X		Name and address of facility: TSDF (Treatment Storage and Disposal Facility) Site Phase II, GIDC, Vatva Ahmedabad 382445 Used oil : Shana Oil process, near good luck market, chandola lake, Ahmedabad 380023.	All the hazardous waste generated is outsourced to an authorized TSDF.
	Is the disposal facility in house?		X		
	Is the disposal facility external/outsourced?	X			
34.	Is a register maintained on production and treatment, and a manifest system followed for transport of hazardous waste from the grantee to treatment facility?	X		Register is maintained on production and treatment, and a manifest system followed for transport of hazardous waste from Intas to treatment facility	Maintenance of register will be continued and manifest system will be followed.

E-Waste and Batteries

	Area of Risk	Yes	No	Details	Proposed Plan
35.	Does the grantee generate e-waste, produce or manufacture electrical and electronic equipment?	X		E-waste such as non working IT equipments are generated. No other electrical or electronic equipment is produced or manufactured	E-waste will be managed through Pruthavi recyclers
36.	Has the grantee obtained SPCB authorization on e-waste?		X	Jagdamba scrap is not authorised to collect E-Waste. Currently our e-waste is managed by Pruthavi recyclers and they are authorised to collect e-waste. Certificate is attached for your reference.	

Environmental Health Risk Management Plan (EHRMP)

Intas Pharmaceutical Limited

37.	Does the grantee channelize the e-waste to authorized recycling or disposal facility?	X		Name and address of disposal facility/ recycler: Pruthavi, Rajkot, Gujarat In-house or outsourced Facility: outsourced	Practice already in place will be followed throughout the Project.
38.	Does the manufacturing grantee have Extended Producer Responsibility system and EPR-authorization in place?		X		
39.	Does the grantee practice reduction in the usage of hazardous substances in the manufacture of electrical and electronic equipment and its parts?		X		
40.	Does the grantee provide detailed information on the constituents of the equipment and their components/spares and declaration of conformation to Reduction in Hazardous Substances in the product user documentation?		X		
41.	Does the grantee maintain a record of collection, storage, sale and transport of e-waste?	X		As per SP-PA-012: Scrap Handling and Campus Solid waste Management, Intas Biopharma facility, records for e-waste is available.	Existing procedures, process and regulatory compliance will be extended and followed throughout the project.
42.	Does the grantee submit annual reports on e-waste to SPCB?		X	Scrap record is available at premises for e-waste and the registered recycler is audited by SPCB	Information shared with SPCB.
43.	Is there accident reporting and records in place?	X		Accident reporting and records in place	Practice already in place and records may be provided on request.
44.	Are PPEs available to staff?	X		SOP on Handling Solid waste talks about PPE	The stock status of PPE will be regularly monitored and procurement will be done in time to avoid any situation of stock out.

Environmental Health Risk Management Plan (EHRMP)

Intas Pharmaceutical Limited

45.	Is the grantee involved in manufacture of batteries?		X	We don't manufacture any kind of batteries.	No proposed plan to manufacture batteries.
46.	Does the grantee generate battery waste?	X		Intas does generate battery waste from UPS. The used batteries are recycled as an exchange from the vendor who is supplying the new batteries. The batteries that are not fit for exchange are being sent to vendor. We are in process to identify vendor for registered recycler for end of life batteries via Intas vendor management system	Existing procedures, process and regulatory compliance will be extended and followed throughout the project.
47.	Does the grantee deposit the battery waste to registered recycler/dealer/manufacture/reconditioner/collection center?	X		We are in process to identify vendor for registered recycler for end of life batteries via Intas vendor management system	Proposed plan in place to handover the battery waste to registered recycler will be followed throughout.
48.	In case of manufacturing, does the grantee comply to Battery Management Rules 2000 and ensure collection of old batteries?	X		We are in process to identify vendor for registered recycler for end of life batteries via Intas vendor management system	Existing procedures, process and regulatory compliance will be extended and followed throughout the project.

Community Health and Safety and risk mitigation

		Yes	No	Details	Proposed Plan
49.	Safety Transportation Management System (for transport Of hazardous material)	X		Membership with Ecocare Infrastructure Pvt. Ltd. For safe transportation & disposal of Hazardous waste. Membership with E-coli	Existing procedures, process and regulatory compliance will be extended and followed throughout

Environmental Health Risk Management Plan (EHRMP)

Intas Pharmaceutical Limited

				waste management for safe transportation & disposal of bio medical waste.	the project.
50.	Emergency preparedness and participation of local authorities and potentially affected communities	X		Emergency response plan available	Emergency response plan practice already in place which will be maintained

Other					
	Area of Risk	Yes	No	Details	Proposed Plan
51.	Does the grantee use any radioactive materials (isotopes, tracers, radiation equipment, etc)?		X		We don't use any radioactive material in our facilities and will not be used in the future also.
	Does the grantee have appropriate radioactive material and waste storage and disposal system in place?		X		
	Are radioactive warning signs in place?		X		
52.	Is the lab/room air regularly checked for microbial contamination?	X		Environmental monitoring program is not available for R&D at Intas Biopharma facility	
53	Are there any odor control measures in place?		X	Polyelectrolytes for damp ETP sludge and then lime is sprayed. Filter press and screw press process is carried out for dry sludge extraction. The dry sludge is filled in polyethylene bags and stored at a safe distance – HW storage area as per GPCP norms	Mentioned practice is in place.
54.	Are fume hoods and exhausts regularly checked and maintained?	X		SOP: SP-EN-155 (preventive maintenance of fume hood) at Intas Biopharma facility	Practice already in place will be carries throughout the project.

Environmental Health Risk Management Plan (EHRMP)

Intas Pharmaceutical Limited

55.	Does the grantee use DG set > 15 KVA?	X		To Check: Inspection report/Certificate available. Consent for DG > 15 KVA available. The emissions from the boilers and DG sets are monitored and are within the prescribed norms.	Monitoring for air emissions will be continued.
	Does the grantee have consent for DG > 15 KVA?	X			
	Are emissions from boilers and DG sets regularly monitored to be within the prescribed norms?	X			
56.	Does the grantee have proper disposal process for solid and plastic waste in compliance to Solid Waste Management Rules, 2016 and Plastic Waste Management Rules, 2016?	X		Describe: SP-PA-012: Scrap Handling and Campus Solid waste Management, Intas Biopharma facility Municipal solid waste is treated in our ETP site and the sludge that is generated is further sent to the registered TSDF site for further processing and disposal. Plastic solid waste that are generated are all sent to the Jagdamba scrap traders, Ahmedabad for recycling.	Solid waste will be segregated and sent to PCB Authorized Vendor. Jagdamba scarp is authorized to lift plastic waste
57.	Is wastewater treated separately by the grantee? (Liquid waste from laboratory, chemicals, fluids, solvents, medium and cultures, coolants, etc.)	X		Types of wastewater: Liquid waste from laboratory, chemicals, fluids, solvents, medium and cultures, coolants Treatment of wastewater: Treated in ETP Chemical management in wastewater treatment plants: all effluents	Periodic checks will be done and the treated water will be sent to ETP.

Environmental Health Risk Management Plan (EHRMP)

Intas Pharmaceutical Limited

				from labs are treated in ETP. Coagulation and flocculation chemicals are used. EHS/PY/006-01 Policy on operation of effluent treatment plant.	
	Are there sludge management and cut off drains in place for wastewater?	X		EHS/PY/006-01 Policy on operation of effluent treatment plant.	The mentioned practice is already in place and will be followed.
58.	Are necessary provisions for noise cancellation in place?	X		Enclosure are built for loud noise escape. Use of PPE such as ear plugs and ear muff.	At R&D we are not anticipating any noise pollution however we are noise monitoring quarterly through GPCB approved consultant. Noise monitoring report attached herewith for your reference.
59.	Are there any settlements, water bodies, cultivated land, or any other eco-sensitive areas near the grantee's premises?		X		
60.	Are there any buffers, fire vehicle routes in the grantee's premises?	X		As per the Intas layout, there are vehicle routes in and around the facility accessible to all the buildings within the premises to ensure buffers and safety.	Will ensure that the premise is well equipped with these essential services which are properly and regularly maintained.
COVID Precautions & Guidelines Implementation					
61.	Guidelines of CPCB/SPCB/GoI for Handling, Treatment, and Disposal of COVID Waste Generated is whether being followed		X	Intas will not generate COVID waste. In the current project, Intas will produce plasmid DNA encoding a segment of spike protein and outsource it to relevant facilities to evaluate its	COVID waste not generated at Intas. In case any waste is being generated in future proper disposal as per guidelines of CPCB/SPCB/GoI will be followed.

Environmental Health Risk Management Plan (EHRMP)

Intas Pharmaceutical Limited

				safety and efficacy. This will not involve any COVID strain or waste.	
62.	SOP on preventive measures to contain spread of COVID-19 issued by ICMR/GoI from time to time is whether being followed	X		Intas follows general guide-line issued by ICMR/GoI to contain spread COVID-19 among employees.	Intas is not involved in generation of any COVID waste through any of its process.

Notwithstanding the above other risk (relevant to the project activities) that will be identified in the course shall be addressed as per standard mitigation monitoring parameters and manner of records keeping shall be in accordance to the recommendations of the project monitoring committee on subject experts engaged by BIRAC.